OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study.

J Immunother Cancer · 2022 · PMC8984036 · PMID 35383116

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In conclusion, this phase Ib trial of unresectable stage IIIC–IV melanoma demonstrated that OrienX010 is safe and well tolerated with a positive trend of antitumor effects and may be a valuable agent for patients with melanoma.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.